BioMarin Pharmaceutical revenue and financials
$56.22Change from previous close: −2.29%Absolute change: −$1.32
In the fiscal year ended December 2025, BioMarin Pharmaceutical reported revenue of $3.22B (+12.87% year over year). Net income was $348.9M, a net margin of 10.8%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +12.87%
- 2025 vs 2024
- Net income growth
- −18.26%
- 2025 vs 2024
- Net margin
- 10.8%
- 2024: 15.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 168 | 221 | 99.6 | 369 | 185 | 174 | 186 | 221 | 119 | 47.0 | 27.5 | 136 |
| Depreciation and amortization | 97.6 | 16.4 | 13.0 | 18.5 | 18.6 | 22.1 | 23.6 | 19.0 | 26.5 | 27.4 | 26.9 | 25.7 |
| Capital expenditure | -28.8 | -20.9 | -40.7 | -28.4 | -17.1 | -16.8 | -19.5 | -18.5 | -21.3 | -26.1 | -28.9 | -21.7 |
| Investing cash flow | -5,102 | 726 | -42.4 | -331 | -12.6 | -28.2 | 76.4 | -16.2 | 90.5 | -14.2 | -65.0 | -45.8 |
| Financing cash flow | 2,738 | 813 | 3.2 | -2.2 | -4.6 | -38.8 | 2.9 | -499 | 12.6 | -42.8 | 10.8 | -0.8 |
| Share repurchases | -11.3 | -28.2 | -2.7 | -2.2 | -12.3 | -38.8 | -4.9 | -5.9 | -16.8 | -49.9 | -3.9 | -4.5 |
| Debt issued | 2,800 | 850 | — | — | 0.0 | 0.0 | — | — | — | — | — | — |
| Debt repaid | — | — | 0.0 | — | — | — | — | -495 | — | — | — | 1.6 |
| Effect of exchange rates | -3.0 | 1.4 | 1.2 | 0.7 | -3.1 | -1.4 | 2.5 | -2.9 | 3.3 | 1.9 | -3.6 | 2.0 |
| Net change in cash | -2,198 | 1,761 | 61.6 | 36.3 | 165 | 106 | 267 | -297 | 225 | -8.1 | -30.3 | 91.0 |
| Free cash flow | 139 | 200 | 58.9 | 340 | 168 | 158 | 166 | 203 | 97.4 | 20.9 | -1.4 | 114 |
| Levered free cash flow | -279 | 160 | 88.7 | 114 | 97.1 | 103 | 78.1 | 166 | 5.6 | -37.2 | 19.3 | 88.6 |